SCHEMBL3826432

SCHEMBL3826432

COCc1cnoc1NC(=O)c1cnccc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.46
POLB P06746 1/20 0.46
DGAT2 Q96PD7 1/20 0.42
MAPT P10636 1/20 0.41
PTGES O14684 3/20 0.40
ALDH1A1 P00352 1/20 0.40
SGMS2 Q8NHU3 1/20 0.39
SCD5 Q86SK9 2/20 0.37
KLKB1 P03952 1/20 0.37
POLQ O75417 1/20 0.37
SCD O00767 1/20 0.37
GMNN O75496 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
HTR1A P08908 1/20 0.37
THRB P10828 1/20 0.37
PIM1 P11309 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1202926 0.89 NPC1 (0.46) NPC1POLBDGAT2MAPTALDH1A1
SCHEMBL3829469 0.87 NPC1 (0.45) NPC1POLBDGAT2MAPTPTGES
SCHEMBL3832549 0.86 NPC1 (0.44) NPC1POLBDGAT2MAPTALDH1A1
SCHEMBL3830626 0.84 NPC1 (0.42) NPC1POLBDGAT2MAPTALDH1A1
SCHEMBL1201890 0.83 MAPT (0.50) NPC1POLBDGAT2MAPTALDH1A1
SCHEMBL3830782 0.83 NPC1 (0.43) NPC1POLBDGAT2MAPTALDH1A1
SCHEMBL27637724 0.82 NPC1 (0.51) NPC1POLBDGAT2MAPTALDH1A1
SCHEMBL3831171 0.82 NPC1 (0.41) NPC1POLBDGAT2MAPTALDH1A1
SCHEMBL3831259 0.82 NPC1 (0.42) NPC1POLBDGAT2MAPTPTGES
SCHEMBL1203021 0.82 NPC1 (0.48) NPC1POLBDGAT2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1460071-B1 N-HETEROARYLNICOTINAMIDE DERIVATIVES MITSUI CHEMICALS AGRO INC (JP) 2009-09-16 EP disclosed
CN-100425609-C N-Heteroaryl Nicotinamide Derivatives SANKYO AGRO CO LTD (JP) 2008-10-15 CN disclosed
US-7015236-B2 N-heteroarylnicotinamide derivatives SANKYO AGRO COMPANY, LIMITED (JP) 2006-03-21 US disclosed
CN-1692111-A N-Heteroaryl Nicotinamide Derivatives SANKYO AGRO CO LTD (JP) 2005-11-02 CN disclosed
US-20050004368-A1 N-heteroarylnicotinamide derivatives SANKYO ARGO COMPANY LIMITED (JP) 2005-01-06 US disclosed
EP-1460071-A1 N-HETEROARYLNICOTINAMIDE DERIVATIVES Sankyo Agro Company, Limited (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004368-A1 N-heteroarylnicotinamide derivatives CBR3, CBR1, NAT1 NPC1 673/4885POLB 3500/4885DGAT2 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.